Methods of treating tardive dyskinesia and other movement disorders

7,745,493

11/340802

January 25, 2006

The present invention describes a novel treatment for movement disorders, including tardive dyskinesia, tic disorders, Tourette's syndrome, and blepharospasm, and other focal dystonias. The treatment of the present invention utilizes agents that simultaneously act as NMDA-type glutamate receptor antagonists and GABA-A receptor agonists. Preferably these two activities are characteristic of a single agent, for example acamprosate. Alternatively, separate agents having these activities can be combined and administered together. The invention also provides a third agent that acts as a non-competitive NMDA-receptor blocking agent or ion channel blocker that augments the effect of the primary treatment. A particularly preferred ion channel blocking agent is magnesium. Alternatively, magnesium can be administered alone for prevention and treatment of movement disorders.

Fogel, Barry S. (Waban, MA, US)

Synchroneuron, LLC (Lexington, MA, US)

1. A method for treating hyperkinesia comprising administering an effective dose of acamprosate in an amount of about 1 g to about 2.6 g per day.

2. The method of claim 1 , wherein said step of administering comprises oral administration.

3. A method of treating a hyperkinetic movement disorder comprising the step of administering an effective dose of acamprosate in an amount of about 1 g to about 2.6 g per day.

4. The method of claim 3 , wherein the hyperkinetic movement disorder is tardive dyskinesia or comprises involuntary movements similar to those seen in said tardive dyskinesia.

5. The method of claim 3 , wherein said movement disorder is the peak-dose dyskinesia in a patient with Parkinson's disease.

6. The method of claim 3 , wherein said movement disorder is associated with Huntington's disease.

7. The method of claim 3 , wherein said movement disorder is related to a deficiency in GABA in the basal ganglia.

8. The method of claim 3 , wherein said movement disorder is related to NMDA-based excitotoxicity.

9. The method of claim 3 comprising the further steps of: selecting an agent that is a noncompetitive antagonist at NMDA receptors; and administering said agent in conjunction with said acamprosate.

10. The method of claim 9 , wherein said agent is memantine or a derivative thereof.

11. The method of claim 1 , wherein the hyperkinesia comprises tardive dyskinesia.

12. A method of treating tardive dyskinesia, comprising providing a patient suffering from tardive dyskinesia with an effective dose of acamprosate in an amount of about 1 g to about 2.6 g per day.

514/665

4122193 October 1978 Scherm et al.
4233229 November 1980 Chakrabarti
4355043 October 1982 Durlach
4582705 April 1986 Primes et al.
5061703 October 1991 Bormann et al.
5262162 November 1993 Bormann et al.
5382601 January 1995 Numberg et al.
5455279 October 1995 Lipton
5474990 December 1995 Olney
5602150 February 1997 Lidsky
5614560 March 1997 Lipton
5952389 September 1999 Fogel

Vetulani (Review Drug Addiction. Part III. Pharmacotherapy of Addiction, Polish Journal of Pharmacology, 2001, vol. 53, pp. 415-434). cited by examiner
G. Bartholini. Medicinal Research Reviews. 5(1):55-75 (1985). cited by other
Berton et al. Alcoholism: Clinical and Experimental Research. 22(1):183-191 (1998). cited by other
Alexander, et al. “Serum Calcium and Magnesium in Schizophrenia: Relationship to Clinical Phenomena and Neuroleptic Treatment.” Brit. F. Psychiat. 133: 143-49 (1978). cited by other
Ananth, et al. “Meige's Syndrome Associated with Neuroleptic Treatment.” Am J. Psychiatry. 145: 4 (Apr. 1988). cited by other
Andrew. “Clinical Relationship of Extrapyramidal Symptoms and Tardive Dyskinesia.” Can. J. Psych. 39: 576-580 (1994). cited by other
Andreassen, et al., “Tardive Dyskinesia: Behavorial Effects of Repeated Intracerebroventricular Haloperidol Injections in Rats Do Not Confirm the Kindling Hypothesis”, Pharmacology Biochemistry and Behavior, 49:2, 309-312, 1994. cited by other
Andreassen, et al., “Inhibition by Memantine of the Development of Persistant Oral Dyskinesias Induced by Long-Term Haloperidol Treatment of Rats”, British Journal of Pharmacology 119: 751-757, 1996. cited by other
Arthurs, et al.; “Treatment of Blepharospasm with Medication, Surgery and Type A Botulinum Toxin”, Can J. Ophthalmol, 22:1, 1987. cited by other
Athanassenas, et al., “Serum Calcium and Magnesium Levels in Chronic Schizophrenics”, Journal of Clinical Psychopharmacology, 3:4, Aug. 1983. cited by other
Bezchilbynk-Butler et al., “Antiparkinsonian Drugs in the Treatment of Neuroleptic-Induced Extrapyramidal Symptoms”, Can. J. Psych., 39:74-84, 1994. cited by other
Boumans et al., “Is the Social Acceptability of Psychiatric Patients Decreased by Orofacial Dyskinesia?”, Schizo Bull, 20:339-344, 1994. cited by other
Britton, et al., “Dextromethorphan Protects Against Cerebral Injury Following Transient, But Not Permanent, Focal Ischemia in Rats” Life Sciences, 60:20, 1729-1740, 1997. cited by other
Büchel et al., “Oral Tardive Dyskinesia: Validation of a Measuring Device Using Digital Image Processing”, Psychopharmacology-Berl, 117:162-165, 1995. cited by other
Casey, D. “Pharmacology of Blepharospasm-Oromandibular Dystonia Syndrome”, Neurology, 30:690-695, Jul. 1980. cited by other
Cassady, et al., “Neuroleptic Induced Movement Disorders”, Cambridge, England: Cambridge University Press, 1997, pp. 454-469. cited by other
Chabenat, et al., “Physicochemical, Pharmacological and Pharmacokinetic Study of a New GABAerigic Compound, Calcium Acetylhomotaurinate”, Methods Find Exp Clin Pharmacol, 10:311-7, May 1988. cited by other
Chakos et al., “Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia”, Arch Gen Psychiatry, 53:313-319, 1996. cited by other
Chappell, et al., “Future Therapies of Tourette Syndrome”,-Neurologic Clinics of North America, 15: May 2, 1997. cited by other
Chen, et al., “Focal Dystonia and Repetitive Motion Disorders”, Clinical Orthopaedics and Related Research, 351: 102-106. cited by other
Dabiri, et al., “Effectiveness of Vitamin E for Treatment of Long-Term Tardive Dyskinesia”, Am J. Psychiatry 151: Jun. 6, 1994. cited by other
Decker et al., “Amantadine Hydrochloride Treatment of Tardive Dyskinesia”, Oct. 7, New England J. Med, 285:860, 1971. cited by other
Delfs et al., “Expression of Glutamic Acid Decarboxylase mRNA in Striatum and Pallidum in a Animal Model of Tardive Dyskinesia”, Exp. Neurol, 133:175-188, 1995. cited by other
De Mattos, et al., “Distonias Aspectos Clinicose E Terapeuticos Bm 64 Pacientes”, Arq. Neuropsiquiatr, 54:30-36, 1996. cited by other
Decollogne, et al. “NMDA Receptor Complex Blockade by Oral Administration of Magnesium: Comparison with Mk-801.” Pharmacology Biochemistry and Behavior. 58(1): 261-268 (1997). cited by other
Dimpfel, “Effects of Memantine on Synaptic Transmission in the Hippocampus in Vitro”, Arzneimittelforschung, 45:1-5, 1995. cited by other
Durlach, et al., “Magnesium Status and Ageing: an Update”, Magnesium Research 11:25-42, 1997. cited by other
Egan M.F., et al., “Treatment of Tardive Dyskinesia” Schizophr Bull, 23(4):583-609 1997. cited by other
Elston, J. “The Management of Blepharospasm and Hemifacial Spasm”, J. Neurol 239:5-8, 1992. cited by other
Erna, et al., “Alcohol-Induced Vascular Damage of Brain is Ameliorated by Administration of Magnesium”, Alcohol, 15:95-103, 1998. cited by other
Erdo et al., “Memantine is Highly Potent in Protecting Cortical Cultures against Excitotoxic Cell Death Evoked by Glutamate and N-Methyl-D-Aspartate”, Eur. J. Pharmacol, 198:215-217, 1991. cited by other
Esper, et al., “Adult-Onset Focal Dystonias: Presentation and Treatment Options”, Tennessee Medicine, Jan. 18-20, 1997. cited by other
Fariello, R.G. et al., “Homotaurine (3 Aminopropanesulfonic Acid; 3APS) Protects Froom the Convulsant and Cytotoxic Effect of Systemically Administered Kainic Acid.” Neurology, 32:241-5, Mar. 1982. cited by other
Galardi, et al., “Basal Ganglia and Thalamo-Cortical Hypermetabolism in Patients with Spasmodic Torticollis”, Acta Neurol Scand 94:172-176, 1996. cited by other
Greensmith, et al., Magnesium Ions Reduce Motoneuron Death Following Nerve Injury or Exposure to N-Methyl-D-Aspartate in the Developing Rat. cited by other
Gao et al., “Tiagabine Inhibits Haloperidol-Induced Oral Dyskinesias in Rats”, J. Neural Transmission, 95:63-69, 1994. cited by other
Gardos, et al., “The Treatment of Tardive Dyskinesias”, Psychopharmacology, 1503-1511, 1995. cited by other
Gullestad, et al., “Magnesium Status in Healthy Free-Living Elderly Norwegians”, Journal of the American College of Nutrition, 13:1,45-50. cited by other
Hallett, M. “The Neurophysiology of Dystonia”, Arch Neurol, 55: May 1998. cited by other
Hayashi et al., “Prevalence of and Risk Factors for Respiratory Dyskinesia”, Clin. Neuropharmacol, 19:390-398, 1996. cited by other
Holds, et al., “Facial Dystonia, Essential Blepharospasm and Hemifacial Spasm”, AFP, 43(6): 2113-2120, Jun. 1991. cited by other
Imamura et al., “Improved Preseveration with Amantadine”, Abstract, No-To-Shinkei, 46:556-562, 1994. cited by other
Jacoby, et al., “Diltiazem Reduces the Contractility of Extraocular Muscles in Vitro and in Vivo”, Investigative Ophthalmology & Visual Science, 31:569-576, Mar. 1990. cited by other
Jankovic, J. “Treatment of Hyperkinetic Movement Disorders with Tetrabenazine: A Double-Blind Crossover Study”, Ann Neurol 11:41-47, 1982. cited by other
Jankovic, J. “Blepharospasm and Orofacial—Cervical Dystonia: Clinical and Pharmacological Findings in 100 Patients”, Ann Neurol 13:402-411, 1983. cited by other
Jeste et al., “Risk of Tardive Dyskinesia in Older Patients. A Prospective Longitudinal Study of 266 Outpatients”, Arch Gen Psychiatry, 52:756-765, 1995. cited by other
Keilhoff et al., “Memantine Prevents Quinolinic Acid-Induced Hippocampal Damage”, Eur. J. Pharmacol, 219:451-454, 1992. cited by other
Kirov, et al., “Plasma Magnesium Levels in a Population of Psychiatric Patients: Correlations with Symptoms”, Neuropsychobiology 30:73-78, 1994. cited by other
Komhuber et al., “New Therapeutic Possibilities with Low-Affinity NMDA Receptor Antagonists”, Abstract, Nervenarzt, 67:77-82, 1996. cited by other
Krielglstein, et al., Apparent Independent Action of Nimodipine and Glutamate Antagonists to Protect Cultured Neurons Against Glutamate-Induced Damage. cited by other
Kurata, et al., “Meige's Syndrome During Long-Term Neuroleptic Treatment”, The Japanese Journal of Psychiatry 43: 627-631, 1989. cited by other
Kurlan, R. “Treatment of Tics”, Neurologic Clinics of North America, 15:2, 403-409, May 1997. cited by other
Lam et al., Vitamin E in the Treatment of Tardive Dyskinesia: A Replication Study, J. Nerv. Ment Dis, 182:113-114, 1994. cited by other
Latimer, “Tardive Dyskinesia: A Review”, Abstract, Can J. Psych, 40:S49-54, 1995. cited by other
Leckman, et al., “Tic Disorders”, The Psychiatric Clinics of North America, 20:4 839-861, Dec. 1997. cited by other
Lichter, et al., “Predictors of Clonidine Response in Tourette Syndrome: Implications and Inferences”, Journal of Child Neurology 11:93-97, Mar. 1996. cited by other
Lipski, et al., A Study of Nutritional Deficits of Long-Stay Geriatric Patients, Age and Agening 22:244-255, 1993. cited by other
Lohr et al., “A Double-Blind Placebo-Controlled Study of Vitamin E Treatment of Tardive Dyskinesia”, J. Clin. Psychiatry, 57:167-173, 1996. cited by other
Lombardini, John B. “Opposite Effects of 2-Aminoethanesulfonic Acid (Taurine) and Aminomethanesulfonic Acid on Calcium Ion Uptake in Rat Retinal Preparations”. cited by other
Martin, et al., “Comparison of Inorganic Elements from Autopsy Tissue of Young and Elderly Subjects”, J. Trace Elem. Electrolytes Health Dis.,5:203-211, 1991. cited by other
Mauriello, et al., “Treatment Selections of 239 Patients with Blepharospasm and Meige Syndrome over 11 Years”, Br. J. Ophthamaol, 80(12):1073-1076, Dec. 1996. cited by other
Mauriello, et al., “Treatment Choices of 119 Patients with Hemifacial Spasm over 11 Years”, Clinical Neurology and Neurosurgery, 98: 213-216, Aug. 1996. cited by other
Meshul, et al., “Correlation of Vacuous Chewing Movements with Morphological Changes in Rats Following 1-Year Treatment with Haloperidol”, Psychopharmacology 125:238-247,1996. cited by other
Micheli, et al., “Continuous Dopaminergic Stimulation in Cranial Dystonia”, Clinical Neuropharmacology, 11:3, 241-249. cited by other
Muller et al., “Noncompetitive NMDA Receptor Antagonists with Fast Open-Channel Blocking Kinetics and Strong Voltage-Dependency as Potential Therapeutic Agents for Alzheimer's Dementia”, Pharmacopsychiatry, 28:113-124, 1995. cited by other
Pahl et al., “Positron-Emission Tomography in Tardive Dyskinesia”, J. Neuropsych Clin. Neurosci, 7:457-465, 1995. cited by other
Panula-Lehto E. et al., “Effects of Taurine, Homotaurine and GABA on Hypothalamic and Striataldopamine Metabolism.”Naunyn Schmiedebergs Arch Pharmacol, 346:57-62, Jul. 1992 Perlmutter, et al., “Decreased [18F] Spiperone Binding in Putamen Idiopathic Focal Dystonia”, The Journal of Neuroscience, 17:843-850, 1997. cited by other
Ploceniak, “Bruxisme et magnesium, mon experience clinique depuis 1980” Communications Libres, 91, suppII, 1990. cited by other
Raja, “The Treatment of Tardive Dyskinesia”, Abstract, Schweiz Arch Neural Psychaitr, 47: 1996. cited by other
Ransmayr, et al., “Pharmacological Study in Meige's Syndrome with Predominant Blepharospasm”, Clinical Neuropharmacology, 11:68-76, 1988. cited by other
Rouhani, S. et al., “Effects of Muscimol or Homotaurine on Sleep-Wake States in Alcohol-dependent rats during Withdrawal.” Pharmacol Biochem Behav, 59:955-60, Apr. 1998. cited by other
Sachdev, “Blinking-blepharospasm after long-term neuroleptic treatment”, The Medical Journal of Australia, 150:341-343, Mar. 20, 1989. cited by other
Sachdev et al., “Negative Symptoms, Cognitive Dysfunction, Tardive Akathisia and Tardive Dyskinesia”, Acta Psychiatr Scand, 93:451-459, 1996. cited by other
Sanberg, et al., “Nicotine for the Treatment of Tourette's Syndrome”, Pharmacol. Ther. vol. 74, 21-25, 1997. cited by other
Sandyk, “Blepharospasm—Successful Treatment with Baclofen and Sodium Valproate”, SA Medical Journal, 64: Dec. 3, 1993. cited by other
Sano et al., “A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease”, The New England Journal of Medicine, vol. 336, No. 17, pp. 1216-1247, Apr. 24, 1997. cited by other
Scahill, et al., “Fluoxetine Has Number Marked Effect on Tic Symptoms in Patients with Tourette's Syndrome: A Double-Blind Placebo-Controlled Study,”Journal of Child and Adolescent Psychopharmacology, 7:75-85, 1997. cited by other
Schulz et al., “Neuroprotective Strategies for Treatment of Lesions Produced by Mitochondrial Toxins: Implications for Neurodegenerative Diseases”, Neuroscience, 71:1043-1048, 1996. cited by other
Shane, et al., “Magnesium Deficiency in Alcohol Addiction and Withdrawal”, Magnes Trace Elem, 92:263-268, 1991. cited by other
Silver et al., “Number Difference in the Effect of Biperiden and Amantadine on Parkinsonian- and Tardive Dyskinesia-type Involuntary Movements: A Double-Blind Crossover, Placebo-Controlled Study in Medicated Chronic Schizophrenic Patients”, Abstract, J. Clin. Psychiatry, 56:167-170, 1995. cited by other
Silver, et al., Case Study: Long-Term Potentiation of Neuroleptics with Transdermal Nicotine in Tourette's Syndrome, J. Am. Chil. Adolesc. Psychiatry, 35: Dec. 12, 1996. cited by other
Stoessl, “Effects of Ethanol in a Putative Rodent Model of Tardive Dyskinesia”, Pharmacol Biochem Behav, 54:541-546, 1996. cited by other
Steingard, Adjunctive Clonazepam Treatment of Tic Symptoms in Children with Comorbid Tic Disorders and ADHD, J. Am. Acad. Child Adolesc. Psychiatry, 33:3, Mar./Apr. 1994. cited by other
Swartz, “Tardive Psychopathology”, Neuropsychobiology, 43:115-119, 1995. cited by other
Tirelli et al., “Differential Effects of Direct and Indirect Dopamine Agonists on the Induction of Gnawing in C57B1/6J Mice”, J. Pharmacol Exp. Ther., 273:7-15, 1995. cited by other
Trube, et al., “Dextromethorphan: Cellular Effects Reducing Neuronal Hyperactivity” Epilepsia. 35:5 S62-S67, 1994. cited by other
Tsai, et al., “Markers of Glutamatergic Neurotransmission and Oxidative Stress Associated with Tardive Dyskinesia”, Am J. Psychiatry 155:9, Sep. 1998. cited by other
Vale et al., “Amantadine for Dyskinesia Tarda”, New Eng. J. Med., 284:673, 1971. cited by other
Van-Rekum et al., “N of 1 Study: Amantadine for the Amotivational Syndrome in a Patient with Traumatic Brain Injury”, Brian Inj. 9:49-53, 1995. cited by other
Vetulani, Jerzy. Drug Addiction. Part III. Pharmacotherapy of Addiction. Polish Journal of Pharmacology. 53: 415-434 (2001). cited by other
Waddington et al., “Cognitive Dysfunction in Chronic Schizophrenia Followed Prospectively Over 10 Years and Its Longitudinal Relationship to the Emergence of Tardive Dyskinesia”, Psychol Med, 26:681-688, 1996. cited by other
Wenk et al., “MK-801, Memantine and Amantadine Show Neuroprotective Activity in the Nucleus Basalis Magnocellularis”, Eur. J. Pharmacol, 293:267-270, 1995. cited by other
Wilde, et al., “Acamprosate”, Adis Drug Evaluation, 53:1038-1053, Jun. 1997. cited by other
Yassa, et al., “Plasma Magnesium in Chronic Schizophrenia”, Int. Pharmacopsychiat. 14:57-64 (1979). cited by other
Ziemann, et al., “Decreased Motor Inhibition in Tourette's Disorder: Evidence From Transcranial Magnetic Stimulation”, Am J Psychiatry, 154:1277-1284, 1997. cited by other

edspgr.07745493